Inhibiting Ewing Sarcoma Cell Growth with Tyrosine Kinase Inhibitors
Author Information
Author(s): Andersson Mattias K, Åman Pierre
Primary Institution: Lundberg Laboratory for Cancer Research, Department of Pathology, Sahlgrenska Academy at Göteborg University, Göteborg, Sweden
Hypothesis
The study investigates the effect of gefitinib and vandetanib on Ewing sarcoma cell lines.
Conclusion
Ewing sarcoma cell proliferation is not significantly affected by inhibiting EGFR and VEGFR signaling alone.
Supporting Evidence
- Both Ewing sarcoma cell lines showed high levels of nuclear EGFR expression.
- Significant decrease in cell proliferation was observed at concentrations of 5 μM and more of gefitinib or vandetanib.
- IC50 values for gefitinib and vandetanib in EWS TC71 were estimated to be ~10 μM and ~5 μM, respectively.
Takeaway
The drugs gefitinib and vandetanib can slow down the growth of certain cancer cells, but they need to be used in high amounts, which might cause other problems.
Methodology
The study used two Ewing sarcoma cell lines and treated them with gefitinib and vandetanib to assess cell proliferation and signaling pathway effects.
Limitations
The study did not determine the IC50 values for one of the cell lines and relied on high drug concentrations that may cause non-specific effects.
Participant Demographics
The study focused on Ewing sarcoma cell lines derived from children and young adults.
Statistical Information
P-Value
p<0.05
Confidence Interval
95.0%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website